Chronic lymphocytic leukemia patients with high-risk genomic features have inferior outcome on successive CALGB trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101

Alemtuzumab consolidation has been investigated to improve remission duration after fludarabine-based induction for chronic lymphocytic leukemia (CLL). The impact on genomic high-risk disease remains unknown. CALGB 19901 and 10101 enrolled previously untreated patients to receive alemtuzumab consoli...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jones, Jeffrey A., Ruppert, Amy S., Zhao, Weiqiang, Lin, Thomas S., Rai, Kanti, Peterson, Bercedis, Larson, Richard A., Marcucci, Guido, Heerema, Nyla A., Byrd, John C.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3766417/
https://ncbi.nlm.nih.gov/pubmed/23547837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.788179
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars